SVASinovac Biotech, Ltd.
$6.47
$0.02
(0.31%)
EarningsNov 6
Mkt Cap$460.27M
SINOVAC Regained Compliance With the Nasdaq Global Markets Listing Requirements
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that...
Business Wire
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the Annual Report) with the U.S. Securities and Exchange Commission. An...
Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
Sinovac Biotech Ltd. (Nasdaq: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the Notification Letter), from Nasdaq Listing Qualifications (Nasdaq) stating that as of May 8, 2026...
Business Wire
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Companys previously declared special cash...
Business Wire
SINOVAC Reports Unaudited First Half of 2025 Financial Results
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June...
Business Wire
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Sinovac Biotech Ltd. (Nasdaq: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal...
Business Wire
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
Sinovac Biotech Ltd. (Nasdaq: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the Panel) has granted the...
Business Wire
Sinovac Biotech Updates Antigua Court Order On Board Composition
(RTTNews) - Sinovac Biotech Ltd. (SVA) announced an update on the Antigua High Court's interlocutory order regarding the Company's board composition and corporate actions pending trial. The Company...
Nasdaq News: Markets
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Courts interlocutory order...
Business Wire
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest SVA News
ViewSINOVAC Regained Compliance With the Nasdaq Global Markets Listing Requirements
Business Wire
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
Business Wire
Advertisement|Remove ads.